Last reviewed · How we verify
NCT06970522
Wearable Sensors to Detect Atypical Muscle Activation in Young Infants
trial in Neuromuscular Disorders in 40 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Shirley Ryan AbilityLab |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 25 June 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Conditions studied
- Neuromuscular Disorders — all drugs for Neuromuscular Disorders →
- Motor Development — all drugs for Motor Development →
- Muscle Tone — all drugs for Muscle Tone →
Sponsor
Shirley Ryan AbilityLab — full company profile →
Who can join
Adults 0 Months to 8 Weeks, any sex, with Neuromuscular Disorders or Motor Development. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and/or identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06970522
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuromuscular Disorders
Currently open trials in the same condition.
- NCT06765070 — Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments · NA · active not recruiting
- NCT06412055 — Bidirectional Tuning of the AFO Stiffness · NA · recruiting
Other Shirley Ryan AbilityLab trials
Trials by the same sponsor.
- NCT07434492 — Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy · Phase 2 · not yet recruiting
- NCT07433023 — tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy · Phase 2 · not yet recruiting
- NCT06999213 — Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors · EARLY_PHASE1 · not yet recruiting
- NCT07032753 — Neuromusculoskeletal Interface for Bionic Arms · NA · not yet recruiting
- NCT07223710 — Improving Walking After Spinal Cord Injury · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06970522 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shirley Ryan AbilityLab
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06970522.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing